shutterstock_204420937 (1) CROPPED

Our Immune Signature Tests are based on RNA bio­marker sig­na­tures obtained from a spe­cific pop­u­la­tion of immune cells, a frac­tion of leuko­cytes. Our tests are based on the reac­tion of the immune sys­tem to malig­nant growth, which occurs long before clin­i­cal man­i­fes­ta­tion.

For the detec­tion of ovar­ian can­cer in high-​risk patient groups, a com­bi­na­tion of RNA and pro­tein bio­mark­ers is currently investigated. The ous­tand­ing unique­ness of this approach is the inte­gra­tion of both, RNA expres­sion bio­mark­ers from spe­cific cells of the immune sys­tem and serum pro­tein bio­mark­ers, into one diag­nos­tic model.

Regarding the detec­tion of breast can­cer, RNA bio­mark­ers are per­fectly ade­quate to dis­crim­i­nate breast can­cer patients from healthy females. The RNA breast can­cer test will be mainly used in case of an unclear mam­mog­ra­phy result to ascer­tain if the woman suf­fers from breast can­cer or not.

Our Immune Signature Tests will be pro­vided for ovar­ian can­cer, breast can­cer, col­orec­tal can­cer, prostate can­cer, and pan­cre­atic cancer.


© OncoLab Diagnostics GmbH 2019

OncoLab Diagnostics GmbH
TFZ - Viktor-Kaplan-Strasse 2, Objekt E
2700 Wiener Neustadt / Lower Austria